2018 – Record Year for Investment and Company Creation

Novo Seeds January 2019 Newsletter

Read the full newsletter here.

• Successful early stage investments made across Life Sciences

• Strong progress with existing portfolio companies

• €135 ($165) million REPAIR Impact Fund off to a great start

• Novo Seeds team expanding with new hires

2018 was a very successful year for our team and our portfolio companies, with six new investments, two portfolio companies closed major financing rounds, the launch of the REPAIR Impact Fund and six new talented colleagues joining.

Our mission is to create and build European life sciences companies based on breakthrough innovation, with the aim of developing novel treatments that can make a major difference to patients’ lives.

We combine new discoveries and entrepreneurs through two routes. The first through our pre-seed program under which we incubate early scientific discoveries to the point where they are ready to attract seed financing and where Novo Seeds will lead to build syndicates of international investors. In addition to our pre-seed program and company creation efforts, we invest in early-stage pre-Proof of Concept biotech and medtech companies throughout Europe in size from €250 thousand to €12.5 million.

This investment strategy enables us to build life sciences companies and attract financing rounds needed to bring them to real inflection points. From a financial perspective we can invest up to €20 million per financing round supporting our portfolio companies to an exit. In 2018, our team reviewed approximately 400 opportunities and made six investments ranging in size from €250,000 to €12.5 million.

Søren Møller, Managing Partner, Novo Seeds comments: “In the Nordics and the rest of Europe we identify breakthrough scientific discoveries that have the potential to deliver innovative therapies and better treatment for patients. As one of the largest company creator teams in Europe, our mission is to create and build life sciences companies developing novel treatments that can make a significant difference to patients’ lives.”

“The successes in 2018 reflect the excellent work done by our team and the achievements across our portfolio of companies. It is testament to our commitment to life sciences that – over the last 10 years – the vast majority of Danish biotechs with International VC investors have been incubated and built by Novo Seeds.”
Søren Møller, Managing Partner, Novo Seeds

In 2018, the Novo Seeds team reviewed approximately 400 opportunities and made six investments ranging in size from €250,000 to €12.5 million. Its investment strategy enables the team to build life sciences companies and attract financing rounds needed to bring them to real inflection points. From a financial perspective the team can invest up to €20 million per financing round supporting portfolio companies to an exit.

For more information, see the full newsletter.